Episode 18 - MDMA Rejection Update & Crucial Lessons for Ketamine Clinics

Dive into the complexities of MDMA therapy rejection, the impacts of the Matthew Perry investigation, and the broader implications for ketamine therapy practices

In this quick episode of the Ketamine Startup Podcast, Sam shares some updates in the psychedelic world, in particular the recent FDA decision on MDMA therapy and the developments in the investigation into Matthew Perry’s death. 

This episode covers the complexities of operating a ketamine clinic amidst recent controversies affecting the public perception of psychedelic therapies. Sam finishes the discussion, with the challenges and responsibilities of providing ketamine treatments responsibly and ethically in today's healthcare environment.

What You'll Learn in This Episode:

• Public Perception and Media Impact: How recent news events shape public perception of ketamine and what clinics can do to educate and reassure their communities.

• Understanding Ketamine's Dual Nature: Learn about the therapeutic potential and risks associated with ketamine, emphasizing the importance of controlled and knowledgeable application in clinical settings.

• Opportunities and Alternatives: Discover what actions you can take and explore alternative treatments like the stellate ganglion block (SGB), and their role in treating PTSD and other conditions.

Listen to the episode on Apple Podcasts, Spotify, Overcast, or on your favorite podcast platform. Watch the discussion on YouTube here.

Episode 18 show notes:

• 00:00 Episode Teaser - Ketamine Can Be UnSafe 

• 00:58 FDA's Decision on MDMA Therapy

• 03:44 Checklist for Starting a Ketamine Clinic

• 04:43 Matthew Perry's Case Updates and Ketamine Safety

• 06:33 Responsible Ketamine Administration

• 10:28 MDMA Rejection and Alternative Treatments - Stellate Ganglion Blocks

• 13:08 Conclusion and Final Thoughts
  

Thanks for listening